| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Half-life: 1.2-2 hours |
|---|---|
| Toxicity/Toxicokinetics |
Toxicity Summary
While the beneficial mechanism of selegiline in treating Parkinson's disease is not fully elucidated, its selective and irreversible inhibition of monoamine oxidase type B (MAO-B) is considered its primary mechanism of action. MAO-B is involved in the oxidative deamination of dopamine in the brain. Selegiline binds to MAO-B in the substantia nigra-striatal pathway of the central nervous system, thereby blocking the metabolism of dopamine by microsomes and enhancing dopaminergic activity in the substantia nigra. Selegiline may also enhance dopaminergic activity through mechanisms other than MAO-B inhibition. At high doses, selegiline can also inhibit monoamine oxidase type A (MAO-A), thus it can be used to treat depression. MAO activity is inhibited when selegiline binds to isorhocin-flavin adenine dinucleotide (FAD) at its active site. Toxicity Data LD50: 63 mg/kg (intravenous injection, rat) (A308) |
| Additional Infomation |
Selegiline is a phenylethylamine alkaloid, tertiary amine, and terminal alkyne compound. It is the conjugate base of selegiline (1+). It is a selective, irreversible monoamine oxidase type B inhibitor. It is used to treat newly diagnosed Parkinson's disease. It can slow the clinical progression of the disease and delay the need for levodopa treatment. It can also be used in combination with levodopa in cases of disability. (From JAMA Drug Evaluation Annals, 1994, p. 385) The compound whose isomer is not specified is selegiline. [PubChem] It is a selective, irreversible monoamine oxidase type B inhibitor used to treat newly diagnosed Parkinson's disease and depression. The compound whose isomer is not specified is selegiline. See also: Selegiline (note moved to).
|
| Molecular Formula |
C13H17N
|
|---|---|
| Molecular Weight |
187.286
|
| Exact Mass |
187.136
|
| CAS # |
2323-36-6
|
| PubChem CID |
5195
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
0.954g/cm3
|
| Boiling Point |
272.5ºC at 760mmHg
|
| Melting Point |
141-142ºC
|
| Flash Point |
108.4ºC
|
| LogP |
2.182
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
14
|
| Complexity |
195
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(CN1CCN(CCOC(C2C=CC(Cl)=CC=2)C2C=CC=CC=2)CC1)O.OC(C(=O)O)=O
|
| InChi Key |
MEZLKOACVSPNER-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3
|
| Chemical Name |
N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine
|
| Synonyms |
(+-)-Deprenyl; Deprenil; Deprenyl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3393 mL | 26.6966 mL | 53.3931 mL | |
| 5 mM | 1.0679 mL | 5.3393 mL | 10.6786 mL | |
| 10 mM | 0.5339 mL | 2.6697 mL | 5.3393 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
